CYT003-QbG10

· Cytos Biotechnology AG

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for CYT003-QbG10, covering 2010-11-15 to 2014-05-14. Get the full timeline:

Most recent: Clinical Trial Update: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma [Phase 2]